The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 6, 2012, Pages 933-937

  Okayasu, Shinji ^a,b   Kitaichi, Kiyoyuki ^a   Hori, Akina ^a   Suwa, Tetsuya ^b   Horikawa, Yukio ^b   Yamamoto, Mayumi ^b   Takeda, Jun ^b   Itoh, Yoshinori ^a  

^a GIFU UNIVERSITY HOSPITAL   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

Diarrhea; Dose optimization; Metformin; Risk factor; Type 2 diabetes mellitus

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN A1C; METFORMIN;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGE; AGED; ANOREXIA; ARTICLE; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE COMPARISON; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HOSPITAL PATIENT; HUMAN; INCIDENCE; JAPANESE; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; VOMITING;

EID: 84861854715     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.933     Document Type: Article

References (26)

1. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab. Vasc. Dis. Res., 5, 157-167 (2008).
2. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst. Rev., CD002966 (2005).
3. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32, 193-203 (2009).
4. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, Køber L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J., 32, 1900-1908 (2011).
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 346, 393-403 (2002).
6. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med., 142, 611-619 (2005).
7. Lee YJ, Jeong JH. A systematic review of metformin to limit weight-gain with atypical antipsychotics. J. Clin. Pharm. Ther., 36, 537-545 (2011).
8. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med., 103, 491-497 (1997).
9. Belcher G, Lambert C, Edwards G, Urquhart R, Matthews DR. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res. Clin. Pract., 70, 53-62 (2005).
10. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev., CD002967 (2010).
11. Juckett G, Trivedi R. Evaluation of chronic diarrhea. Am. Fam. Physician, 84, 1119-1126 (2011).
12. Manatsathit S, Dupont HL, Farthing M, Kositchaiwat C, Leelakusolvong S, Ramakrishna BS, Sabra A, Speelman P, Surangsrirat S, Working Party of the Program Committ of the Bangkok World Congress of Gastroenterology 2002. Guideline for the management of acute diarrhea in adults. J. Gastroenterol. Hepatol., 17 (Suppl.), S54-S71 (2002).
13. Thomas PD, Forbes A, Green J, Howdle P, Long R, Playford R, Sheridan M, Stevens R, Valori R, Walters J, Addison GM, Hill P, Brydon G. Guidelines for the investigation of chronic diarrhoea, 2nd edition. Gut, 52 (Suppl. 5), v1-v15 (2003).
14. Chassany O, Michaux A, Bergmann JF. Drug-induced diarrhoea. Drug Saf., 22, 53-72 (2000).
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41 (1976).
16. Bennett WL, Wilson LM, Bolen S, Maruthur N, Singh S, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Nicholson WK, Block L, Odelola O, Dalal DS, Ogbeche GE, Chandrasekhar A, Hutfless S, Bass EB, Segal JB. "Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update.": 〈http://www.ncbi.nlm.nih.gov/books/NBK55754〉, Rockville MD, Agency for Healthcare Research and Quality, U.S., March, 2011.
17. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med., 355, 2427-2443 (2006).
18. Nammour FE, Fayad NF, Peikin SR. Metformin-induced cholestatic hepatitis. Endocr. Pract., 9, 307-309 (2003).
19. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, Schaeffeler E. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology, 50, 1227-1240 (2009).
20. Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. Diabetes Metab., 37, 90-96 (2011).
21. Caspary WF, Zavada I, Reimold W, Deuticke U, Emrich D, Willms B. Alteration of bile acid metabolism and vitamin-B12-absorption in diabetics on biguanides. Diabetologia, 13, 187-193 (1977).
22. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet. Med., 15, 651-656 (1998).
23. Cuthbertson J, Patterson S, O'Harte FP, Bell PM. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism, 60, 52-56 (2011).
24. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE, DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet, 376, 431-439 (2010).
25. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 368, 1696-1705 (2006).
26. Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, Benet LZ, Karam JH. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J. Clin. Pharmacol., 36, 1012-1021 (1996).